Translational research insights from completed HIV vaccine efficacy trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue SUPPL. 2, 2013, Pages

  Tieu, Hong Van ^a,b   Rolland, Morgane ^b,c   Hammer, Scott M ^b,d   Sobieszczyk, Magdalena E ^b  

^a NEW YORK BLOOD CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

Clinical trials; Efficacy trials; HIV vaccine; Vaccine design

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; VACCINATION; VIRUS REPLICATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84880243963     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829a3985     Document Type: Article

References (69)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
5. International AIDS Vaccine Initiative. IAVI Report Database of AIDS Vaccine Candidates in Clinical Trials [Database Online]. New York, NY; 2013. Available at: http://www.iavireport.org/trials-db/Pages/default.aspx.
6. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS. 2012;26:1293-1302.
7. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654-665.
8. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194:1661-1671.
9. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epide-miologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2004;37:1385-1392.
10. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis. 2005;192:974-983.
11. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173:340-348.
12. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-4655.
13. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis. 2006;43:500-511.
14. Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med. 2007;356:2073-2081.
15. Letvin NL, Schmitz JE, Jordan HL, et al. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus. Immunol Rev. 1999;170:127-134.
16. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283:857-860.
17. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
18. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881-1893.
19. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11:507-515.
20. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372:1894-1905.
21. Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012;206:258-266.
22. Rolland M, Tovanabutra S, deCamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17:366-371.
23. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012;13:423-427.
24. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
25. Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206:431-441.
26. Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis. 2013;207:1195-1205.
27. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-1286.
28. Baden LR, Dolin R. The road to an effective HIV vaccine. N Engl J Med. 2012;366:1343-1344.
29. Forthal DN, Gabriel EE, Wang A, et al. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012;120:2836-2842.
30. Forthal DN, Gilbert PB, Landucci G, et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007;178:6596-6603.
31. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417-420.
32. Karasavvas N, Billings E, Rao M, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012; 28:1444-1457.
33. Zolla-Pazner S, deCamp AC, Cardozo T, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PloS One. 2013;8:e53629.
34. Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176-186.
35. Gorny MK, Pan R, Williams C, et al. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology. 2012;427:198-207.
36. Alter G, Ackerman ME. What mAbs tell us about shapes: multiple roads lead to Rome. Immunity. 2013;38:8-9.
37. Plotkin SA, Robinson HL, Davenport MP. Mining the mechanisms of an HIV vaccine. Nat Med. 2012;18:1020-1021.
38. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008;82:11651-11668.
39. Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85:9998-10009.
40. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011;85:11502-11519.
41. Walker LM, Simek MD, Priddy F, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010;6:e1001028.
42. Stamatatos L, Morris L, Burton DR, et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. Aug 2009;15:866-870.
43. Doria-Rose NA, Louder MK, Yang Z, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol. 2012;86:3393-3397.
44. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481:81-84.
45. Robertson DL, Sharp PM, McCutchan FE, et al. Recombination in HIV-1. Nature. 1995;374:124-126.
46. Jetzt AE, Yu H, Klarmann GJ, et al. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol. 2000;74: 1234-1240.
47. Zhuang J, Jetzt AE, Sun G, et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol. 2002;76: 11273-11282.
48. Dykes C, Balakrishnan M, Planelles V, et al. Identification of a preferred region for recombination and mutation in HIV-1 gag. Virology. 2004; 326:262-279.
49. Galli A, Kearney M, Nikolaitchik OA, et al. Patterns of human immunodeficiency virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersub-type recombinants during replication. J Virol. 2010;84:7651-7661.
50. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immuno-dominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212-217.
51. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med. 1996;124: 984-994.
52. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997;94:1890-1895.
53. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149.
54. Telenti A. Adaptation, co-evolution, and human susceptibility to HIV-1 infection. Infect Genet Evol. 2005;5:327-334.
55. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
56. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991;354:453-459.
57. Koup RA. Virus escape from CTL recognition. J Exp Med. 1994;180: 779-782.
58. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A. 2005;102:18514-18519.
59. Burton DR, Poignard P, Stanfield RL, et al. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012;337:183-186.
60. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105:7552-7557.
61. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206: 1273-1289.
62. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705-742.
63. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469-476.
64. Mouquet H, Nussenzweig MC. HIV: roadmaps to a vaccine. Nature. 2013;496:441-442.
65. Esparza J. Understanding the efficacy variables of an HIV vaccine trial. Lancet Infect Dis. 2012;12:499-500.
66. Benmira S, Bhattacharya V, Schmid ML. An effective HIV vaccine: a combination of humoral and cellular immunity? Curr HIV Res. 2010; 8:441-449.
67. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med. 2011;17:1194-1195.
68. Burton DR, Ahmed R, Barouch DH, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe. 2012;12:396-407.
69. Fuchs JD, Sobieszczyk ME, Hammer SM, et al. Lessons drawn from recent HIV vaccine efficacy trials.J Acquir Immune Defic Syndr. 2010;55 (suppl 2):S128-S131.